JOURNAL OF HEPATOLOGY, cilt.50, sa.2, ss.289-295, 2009 (SCI-Expanded)
Background/Aims: To evaluate the off-treatment durability of response in HBeAg-negative chronic hepatitis B patients who achieved a protocol-defined 'Response' (HBV-DNA < 0.7 MEq/mL and ALT < 1.25 x ULN) with entecavir at 48 weeks and the efficacy of entecavir in patients treated beyond one year.